BRESCAP is under clinical development by Alloksys Life Sciences and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect BRESCAP’s likelihood of approval (LoA) and phase transition for Acute Renal Failure (ARF) (Acute Kidney Injury) took place on 12 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BRESCAP Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

BRESCAP overview

bRESCAP (recombinant bovine alkaline phosphate) is under development for the treatment of Coronavirus disease 2019 (COVID-19), severe burns, acute kidney complications from ischemic injury after open heart surgery, reducing the pro-inflammatory post-surgical responses in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. The drug candidate is administered through intravenous bolus, subcutaneous route as a solution. The drug candidate targets cytokines like tumor necrosis factor-alpha (TNF alpha). The drug candidate is a recombinant bovine alkaline phosphatase developed from bovine intestinal mucosal linings, which has been shown to efficiently express glycosylated proteins, it is based on the RESCAP platform. It was also under development for the treatment of rheumatoid arthritis and ischemia reperfusion injury in living kidney transplantation.

Alloksys Life Sciences overview

Alloksys Life Sciences (Alloksys) operates as a drug development company that develops therapies for patients clinicians and researchers. The company manufactures therapeutic proteins for the treatment of chronic and acute inflammatory diseases. Its therapeutic platform RESCAP is used for preventing adverse downstream complications such as systemic inflammations, issue damage and organ failure during and after major surgery. RESCAP also protects maintains and restores physiological barriers, such as Blood Brain Barrier(BBB), Lung Alveolar Barrier(LAB), Kidney Glomerulus Barrier (KGB) Lung Alveolar Barrier(LAB), Gut Barrier (GB) and Placental Barrier (PB). Alloksys is headquartered in Wageningen, the Netherlands.

Quick View BRESCAP LOA Data

Report Segments
  • Innovator
Drug Name
  • BRESCAP
Administration Pathway
  • Intravenous Bolus
  • Subcutaneous
Therapeutic Areas
  • Cardiovascular
  • Dermatology
  • Genito Urinary System And Sex Hormones
  • Immunology
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.